{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T11:41:10Z","timestamp":1696592470493},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,10]]},"DOI":"10.1093\/bjd\/ljac080","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T14:17:48Z","timestamp":1674224268000},"page":"163-163","source":"Crossref","is-referenced-by-count":0,"title":["Safety of baricitinib in patients with alopecia areata"],"prefix":"10.1093","volume":"188","author":[{"given":"Robert","family":"Bissonnette","sequence":"first","affiliation":[{"name":"Innovaderm Research Inc. , Montreal, Quebec , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"2023100520302358300_ljac080-B1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023100520302358300_ljac080-B2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023100520302358300_ljac080-B3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2023100520302358300_ljac080-B4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2023100520302358300_ljac080-B5","article-title":"Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box","author":"Misra","year":"2022  20","journal-title":"Clin Rheumatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac080\/48362057\/ljac080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/2\/163\/51899162\/ljac080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/2\/163\/51899162\/ljac080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:53:38Z","timestamp":1696539218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/2\/163\/6795230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":5,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,3]]},"published-print":{"date-parts":[[2023,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac080","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,11,3]]}}}